Philip C. Robinson

Herston Road
Herston, QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 200 publications

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

Journal: The Lancet. Infectious diseases

Published: April 05, 2026

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study.

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 30, 2026

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.

Journal: Annals of the American Thoracic Society

Published: October 03, 2025

Repetitive Exposure to Nicotine-Free Vaping Impairs Airway Defences and Delays Recovery.

Repetitive Exposure to Nicotine-Free Vaping Impairs Airway Defences and Delays Recovery.

Journal: Lung

Published: October 01, 2025

Contemporary seasonal human coronaviruses display differences in cellular tropism compared to laboratory-adapted reference strains.

Contemporary seasonal human coronaviruses display differences in cellular tropism compared to laboratory-adapted reference strains.

Journal: Journal of virology

Published: August 27, 2025

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Journal: American journal of respiratory and critical care medicine

Published: August 11, 2025

Patient experiences and perspectives of DMARD monitoring in Australians with long-disease-duration rheumatoid arthritis and psoriatic arthritis.

Patient experiences and perspectives of DMARD monitoring in Australians with long-disease-duration rheumatoid arthritis and psoriatic arthritis.

Journal: BMC rheumatology

Published: May 25, 2025

The Impact of Bushfire Smoke Exposure on Airway Epithelium and Protective Cilia.

The Impact of Bushfire Smoke Exposure on Airway Epithelium and Protective Cilia.

Journal: Journal of applied toxicology : JAT

Published: May 09, 2025

Wide Spectrum of Disease Manifestations in Siblings With Primary Ciliary Dyskinesia Carrying DNAJB13 Mutations: A Case Study.

Wide Spectrum of Disease Manifestations in Siblings With Primary Ciliary Dyskinesia Carrying DNAJB13 Mutations: A Case Study.

Journal: Journal of paediatrics and child health

Published: December 17, 2024

How is gout currently managed, and is there interest in changing the way we deliver care? A qualitative exploratory study.

How is gout currently managed, and is there interest in changing the way we deliver care? A qualitative exploratory study.

Journal: Australian journal of general practice

Published: November 05, 2024

Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.

Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.

Journal: The Lancet. Respiratory medicine

Published: October 17, 2024

The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19.

The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19.

Journal: The Journal of infection

Published: February 20, 2024

Showing 1-12 of 200

Last Updated: 09/26/2026